[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":715},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,44,0,25,[9,44,70,96,122,143,165,189,221,250,280,306,328,358,401,428,454,478,524,549,577,608,629,658,689],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100641888","impact-of-steatotic-liver-disease-associated-with-metabolic-dysfunction-masld-on-frailty-cognition-and-quality-of-life-a-gender-sensitive-approach-towards-a-comprehensive-and-equitable-perspective-100641888",false,"NCT07652892","Impact of Steatotic Liver Disease Associated With Metabolic Dysfunction (MASLD) on Frailty, Cognition, and Quality of Life. A Gender-sensitive Approach Towards a Comprehensive and Equitable Perspective.","IIBSP-MAS-2025-133","MASLD","Inclusion Criteria:\n\n* Patients will be included who are able to provide informed consent and actively participate in periodic assessments.\n\nExclusion Criteria:\n\n* Risky alcohol consumption:\n\n\\> 30 g\u002Fday in men and \\> 20 g\u002Fday in women. AUDIT score: \\> 7 points in men, \\> 5 in women.\n\n* Other liver diseases (viral hepatitis, autoimmune hepatitis, etc.).\n* Advanced neurodegenerative diseases or severe psychiatric disorders.\n* Severe comorbidities or treatments that, in the researchers' judgment, may affect frailty and quality of life more than metabolic syndrome and liver disease.","ALL","20 Years","80 Years",{"count":22,"type":23},140,"ESTIMATED","12 Months","OBSERVATIONAL","The goal of this observational study is to determine the differences in the prevalence, characteristics and evolution of frailty between men and women diagnosed with MASLD, and to establish its relationship with clinical, functional, hormonal and social parameters.",[28],"Steatosis of Liver",[30],"A condition characterized by the accumulation of fat in the liver, which is closely linked to metabolic disorders and occurs with low or no alcohol consumption.","RECRUITING","2026-06-11",{"date":34,"type":35},"2026-06-17","ACTUAL",{"date":37,"type":23},"2026-05-26",{"date":39,"type":23},"2028-05-25",{"name":41,"class":42},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","OTHER",2,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":18,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100639790","biomechanical-evaluation-with-finite-element-models-in-thumb-carpometacarpal-osteoarthitis-prospective-comparative-analysis-of-loads-in-arthroplasty-with-or-without-implants-100639790","NCT07614269","Biomechanical Evaluation With Finite Element Models in Thumb Carpometacarpal Osteoarthitis: Prospective Comparative Analysis of Loads in Arthroplasty With or Without Implants","Inclusion Criteria:\n\n* Primary Osteoarthritis in thumb CMC joint in the hand\n* Adults aged between 50 and 88 years old included.\n* Thumb CMC joint osteoarthritis, radiographic stages II, III and IV by Eaton- Littler classification (1973).\n\nExclusion Criteria:\n\n* Asymptomatic primary osteoarthritis in thumb CMC joint\n* Patients with osteoarthritis and age less than 50 years or more than 88 years.\n* Patients who have had previous interventions in the area, in this joint, injuries in this hand or fractures.\n* Patients with rheumatic diseases or collagen diseases that create joint instability.\n* Patients with physical or mental conditions that preclude intervention.\n* Thumb CMC joint osteoarthritis, radiographic stages I by Eaton-Littler classification (1973)","50 Years","88 Years",{"count":53,"type":23},40,"To better understand the load distribution in the Thumb Carpometacarpal Joint (CMC joint) in presence of osteoarthritis and how surgery by means of a suspension-resection arthroplasty or a joint replacement by means of a metal prosthesis affects this load distribution. These studies allow to supporting medical decisions and surgical treatments results with biomechanical evidence.The clinical management of the patients will be adapted to the treatment standards of the Orthopedic Surgery and Traumatology Service of the Hospital de la Santa Creu i Sant Pau, without the performance of this study influencing this process.",[56],"Thumb Carpometacarpal Joint Osteoarthritis",[58,59,60],"Thumb carpometacarpal joint osteoarthritis","carpometacarpal prosthesis","Thumb carpometacarpal arthroplasty","NOT_YET_RECRUITING","2026-05-25",{"date":64,"type":35},"2026-05-29",{"date":66,"type":23},"2026-06-15",{"date":68,"type":23},"2026-12-31",{"name":41,"class":42},{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":12,"sex":18,"minAge":78,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":80,"phases":81,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":43},"100565893","phase-1-afatinib-in-patients-with-fanconi-anemia-fa-and-advanced-head-and-neck-squamous-cell-carcinoma-hnscc-100565893","NCT06648096","Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)","Phase Ib\u002FII Study to Investigate the Safety and Efficacy of Afatinib When Administered as Therapy in Fanconi Anemia Patients With Unresectable and \u002F or Metastatic Locoregionally Advanced Squamous Cell Carcinoma of the Oral Cavity, Oropharynx or Hypopharynx or Larynx.","AFAN","Inclusion Criteria:\n\n1. Written informed consent according to local guidelines, must be signed and dated by the participant and investigator prior to performing any protocol procedure.\n2. Patient is ≥ 18 years of age.\n3. Confirmed diagnosis of Fanconi anemia.\n4. Histologically or cytologically confirmed unresectable or locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, paranasal sinuses or salivary glands. Patients with distal metastasis (M1, American Joint Cancer Committee (AJCC) 8th ed.) are also eligible.\n5. Tumor not a candidate for resection prior to Afatinib due to technical inability to resect (tumor fixation \u002F invasion in the skull base, cervical vertebrae, nasopharynx or fixed lymph nodes) and \u002F or low surgical cure \\[T3-T4, N2-N3; , AJCC 8th ed.\\]).\n6. Patients must have at least 1 measurable lesion by computed tomography (CT) scan or magnetic resonance imaging (MRI) as defined by RECIST v1.1.\n7. Previous anticancer treatment is allowed if it ends 6 weeks or 5 half-lives, whichever is shorter, before the expected date of start of the study treatment.\n8. Previous locoregional treatments such as radiotherapy are allowed.\n9. Eastern Cooperative Oncology Group (ECOG) performance status \\\u003C 2 at inclusion.\n10. Adequate organ and bone marrow functions, as defined below:\n\n    1. Neutrophils \\> 1000 cells \u002F microliter.\n    2. Platelets \\> 50,000 cells \u002F microliter.\n    3. Hemoglobin \\> 8 g \u002F dL\n    4. Creatinine \\\u003C 1.5 x upper limit normal (ULN) with clearance \\> 50 mL \u002F min.\n    5. Total bilirubin \\\u003C 1.5 x ULN. Note: patients with Gilbert's may be included with bilirubin \\\u003C2 x ULN.\n    6. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C 2.5 x ULN or \\\u003C 5 ULN if liver metastases are present.\n    7. International normalized ratio (INR) and prothrombin time (PT) \\\u003C1.5 x ULN.\n11. Female patients must either:\n\n    1. Be of non-childbearing potential:\n\n       Postmenopausal \\*(defined as at least 1 year without any menses) prior to screening , or Documented surgically sterile (e.g.hysterectomy, bilateral salpingectomy, bilateral oophorectomy, or bilateral tubal occlusion).\n\n       \\*Those who are amenorrheic due to an alternative medical cause are not considered postmenopausal and must follow the criteria for childbearing potential subjects.\n\n       OR\n    2. If of childbearing potential:\n\n    Agree not to try to become pregnant during the study and for at least 1 months after the final study drug administration, And have a negative urine or serum pregnancy test within 7 days prior to Day 1 (females with false positive results and documented verification of negative pregnancy status are eligible for participation), And if heterosexually active, agree to abstinence (if in line with the usual preferred lifestyle of the patient) or consistently use a condom plus 1 form of highly effective birth control per locally accepted standards starting at screening and throughout the study period and for at least 1 month after the final study drug administration.\n12. Female patients must agree not to breastfeed or donate ovules starting at screening and throughout the study period, and for at least 1 month after the final study drug administration.\n13. Male patients must not donate sperm starting at screening and throughout the study period, and for at least 1 month after the final study drug administration.\n14. Male patients with a partner with childbearing potential, or who is pregnant or breastfeeding must agree to abstinence or use a condom plus 1 form of highly effective birth control throughout the study period and for at least 1 month after the final study drug administration.\n15. Patient agrees not to participate in another interventional study while on treatment in the present study.\n\nExclusion Criteria:\n\n1. Patients who are candidates for surgery with curative intent are not eligible.\n2. Less than two weeks from surgical resection or other major surgical procedure at start of treatment. Planned surgery for other diseases.\n3. Previous treatment with EGFR small molecule inhibitors, EGFR inhibitory antibodies and \u002F or any investigational agents for the treatment of HNSCC within 4 weeks prior to the selection was not allowed.\n\n   Note: Previous treatment with chemotherapy and\u002For radiotherapy is allowed.\n4. Patient must have recovered from any previous treatment toxicity to Grade ≤ 2.\n5. Existence of any other intercurrent malignant disease is not allowed within the previous 2 years to inclusion.\n\n   Note: Patients with non melanoma skin cancer, curatively treated localized prostate cancer, or carcinoma in situ of any type (if complete resection was performed) are allowed.\n6. Active severe Severe infectious disease in the 4 weeks prior to the initiation of study treatment, including . Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.\n7. Patient has documented history of a cerebral vascular event (stroke or transient ischemic attack), or the following criteria for cardiac disease:\n\n   1. Myocardial infarction or unstable angina pectoris within 6 months of enrollment.\n   2. History of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication); history of QT interval prolongation.\n   3. New York Heart Association (NYHA) class III or greater congestive heart failure or left ventricular ejection fraction of \\\u003C 40%.\n8. Participants with QTc interval (corrected) \\> 470 msec at screening.\n9. History of interstitial lung disease requiring corticosteroids or pneumonitis.\n10. Gastrointestinal disorders that may interfere with the absorption of the study drug or chronic diarrhea.\n11. Patient has known hypersensitivity to afatinib or to any excipient contained in the drug formulation.\n12. Female patients who are or intend to be pregnant or breastfeeding during their participation in the study or 1 month after the final study drug administration.\n13. Patients unable to comply with the protocol as determined by the investigator.\n14. The patient is currently participating in another clinical trial that would interfere with the radiological imaging schedule or any other determinations required in this protocol.\n15. Patient has other underlying medical conditions that, in the opinion of the investigator, would impair the ability of the patient to receive or tolerate the planned treatment and follow-up.\n16. Patients with psychiatric disorders that may interfere with monitoring.","18 Years",{"count":7,"type":23},"INTERVENTIONAL",[82,83],"PHASE1","PHASE2","This research study is a phase Ib\u002FII, single-arm, non-randomized, non-blind, multicenter study designed to determine whether Afatinib is effective and safe in patients with locoregionally unresectable and \u002F or metastatic HNSCC with Fanconi Anemia.\n\nThe main hypothesis, based on preclinical evidence, is that treatment with afatinib, an epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), could be an effective treatment option to control cancer for patients with FA - HNSCC.",[86,87],"Fanconi Anemia","Head and Neck Squamous Cell Carcinoma","2026-05-22",{"date":90,"type":35},"2026-05-27",{"date":92,"type":35},"2024-11-08",{"date":94,"type":23},"2028-12",{"name":41,"class":42},{"id":97,"slug":98,"hasResults":12,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":12,"sex":18,"minAge":78,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":120,"locationsCount":121},"100551502","3d-printing-models-in-surgical-planning-of-osteotomies-in-kienbocks-disease-stages-ii-iii-100551502","NCT06460922","3D Printing Models in Surgical Planning of Osteotomies in Kienbock´s Disease Stages II-III","3D Printing Models and Personalized Guides in Surgical Planning of Shortening, Wedge and Dorsolateral Biplane Closing Osteotomies in Kienbock´s Disease Stages II and III.","Inclusion Criteria:\n\n* Kienbock´s disease in the wrist estages II, IIIA, IIIB or IIIC by Lichtman classification\n\nExclusion Criteria:\n\n* Pre-radiological stages-Lichtman stage I\n* Radiocarpal and midcarpal osteoarthrosis, Lichtman stage IV\n* Kienböck in children: less than 18 years\n* Adults years greater than 85 years old","85 Years",{"count":105,"type":23},20,"Ischemic necrosis of lunate bone, osteonecrosis or Kienböck´s disease was described by Kienböck in 1910. Numerous surgical procedures for this disease had been proposed. These surgical options, that depends of the radiological stage and anatomical risk factors, can be classified into lunate unloading procedures, lunate revascularization, replacement procedures and salvage procedures. These procedures, except the salvage procedures, has been successful in reconstructing and maintaining the height of the carpus, avoiding progression of the disease and with reduction of the pain.\n\nThe lunate unloading procedures are surgical treatments that make a radial osteotomy for modify differents anatomical risk factors associated with the osteonecrosis.",[108],"Kienbock Disease",[110,111,112,113],"Lunatomalacia","Kienböck´s disease","Radial osteotomy","Biplane radial osteotomy","2026-05-11",{"date":116,"type":35},"2026-05-12",{"date":118,"type":35},"2024-05-10",{"date":68,"type":23},{"name":41,"class":42},1,{"id":123,"slug":124,"hasResults":12,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":129,"enrollmentInfo":130,"targetDuration":129,"studyType":25,"phases":4,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":4},"100636733","development-of-preterm-infants-born-during-the-covid-19-pandemic-100636733","NCT07569523","Development of Preterm Infants Born During the COVID-19 Pandemic","Estudio Del Desarrollo de Los niños Prematuros Nacidos Durante la Pandemia Por el COVID-19","Inclusion Criteria:\n\n* Preterm babies (\\\u003C34 weeks of gestation) born between March 2020 and December 2021 for case group).\n* Preterm babies (\\\u003C34 weeks of gestation) born between January 2023 to December 2024 (control group).\n* Babies who were admitted to the NICU of the Hospital de Sant Pau.\n* Babies who were followed up in External Consultations of the same hospital at least until their first year of age.\n\nExclusion Criteria:\n\n* Preterm infants ≥34 weeks or preterm born outside the periods described in the inclusion criteria.\n* Concurrent diagnosis of genetic pathology or major malformations.\n* Families who discontinued follow-up or did not attend scheduled appointments.","5 Years",{"count":131,"type":23},120,"This study aims to evaluate differences in cognitive and psychomotor development among preterm infants (born before 34 weeks of gestation) delivered during the COVID-19 pandemic at Hospital de la Santa Creu i Sant Pau, compared with a control group of preterm infants born at the same hospital.",[134,135],"Preterm Infant Development","COVID - 19","2026-05-06",{"date":114,"type":35},{"date":139,"type":23},"2026-05",{"date":141,"type":23},"2029-12",{"name":41,"class":42},{"id":144,"slug":145,"hasResults":12,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":12,"sex":18,"minAge":78,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":80,"phases":153,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":4},"100636736","clinical-organizational-and-care-impact-of-the-getready-digital-platform-as-a-clinical-decision-support-tool-in-the-follow-up-of-patients-with-cerebral-aneurysm-100636736","NCT07569562","Clinical, Organizational, and Care Impact of the GetReady Digital Platform as a Clinical Decision Support Tool in the Follow-up of Patients With Cerebral Aneurysm","Smart Aneurysm FOllow-up","SAFO","Inclusion Criteria:\n\n* Diagnosis of cerebral aneurysm\n* Access to one of the following: compatible mobile phone, computer, or tablet with internet access\n* Sufficient internet connection for use of the digital platform\n* When the patient cannot or does not wish to use the application directly, participation may occur through a designated caregiver or family member, after informed consent\n\nExclusion Criteria:\n\n* Patients treated with surgical clipping\n* Absence of informed consent",{"count":152,"type":23},200,[154],"NA","This study evaluates the clinical, organizational, and care impact of the GetReady digital platform as a clinical decision support tool for the follow-up of patients with cerebral aneurysm. The platform integrates clinical, radiological, and patient-reported data, including PROMs and PREMs, and may incorporate home blood pressure monitoring. The study is an interventional implementation study with retrospective and prospective components. No additional medical, diagnostic, or therapeutic intervention is introduced, and all clinical decisions remain under routine clinical practice.",[157],"Intracranial Aneurysms","2026-04-29",{"date":136,"type":35},{"date":161,"type":23},"2026-05-18",{"date":163,"type":23},"2028-12-31",{"name":41,"class":42},{"id":166,"slug":167,"hasResults":12,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":18,"minAge":78,"maxAge":50,"enrollmentInfo":172,"targetDuration":4,"studyType":80,"phases":174,"briefSummary":175,"conditions":176,"keywords":179,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":121},"100635376","phase-2-oxytocin-plus-self-compassion-training-in-borderline-personality-disorder-100635376","NCT07551882","Oxytocin Plus Self-compassion Training in Borderline Personality Disorder","Efficacy of Oxytocin Plus Self-compassion Training Combination in Patients With Borderline Personality Disorder","Inclusion Criteria:\n\n* Diagnosis of Borderline Personality Disorder (BPD) according to two semi-structured interviews: the Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II) and the Revised Diagnostic Interview for Borderlines (DIB-R).\n* Aged between 18 and 50 years, inclusive.\n* Pharmacological treatment stability maintained throughout the intervention period.\n* Previous treatment for BPD, specifically Standard Dialectical Behavior Therapy (DBT) or DBT Skills Training.\n* High levels of self-criticism, defined as scores \\> 12 on the Inadequate Self (IS) subscale of the Forms of Self-Criticizing\u002FAttacking \\& Self-Reassuring Scale - Short Form (FSCRS-SF).\n\nExclusion Criteria:\n\n* Presence of comorbid psychiatric disorders, including: Schizophrenia, Psychotic Disorders, Bipolar Disorder, Current Major Depressive Disorder (MDD), Substance Dependence, Organic Brain Disease, or Intellectual Disability, as determined by medical examination and clinical assessment using the SCID-I (Structured Clinical Interview for DSM-IV Axis I Disorders).\n* History of severe endocrine disorders.\n* History of medical conditions, specifically: Epilepsy, Renal Insufficiency (Kidney Failure), or Heart Failure.\n* Concurrent participation in any other psychotherapy or psychological treatment during the study period.\n* Women of childbearing potential who are unwilling or unable to use highly effective contraception (e.g., oral contraceptives, intrauterine device \\[IUD\\], partner's vasectomy, tubal ligation, or sexual abstinence) throughout the entire duration of the study.\n* Intention to become pregnant or planning a pregnancy during the course of the study.\n* Current pregnancy or breastfeeding at the time of enrollment or during the study.\n* Concomitant medical treatment that is incompatible with the administration of intranasal oxytocin.",{"count":173,"type":23},80,[83],"Background: Borderline personality disorder (BPD) is a frequentand serious psychiatric disorder characterized by a persistent pattern of instability in relationships, affect and self-image. Although long-term follow-up prospective studies have shown high clinical remission rates, they also point out that usually persist social functioning deficits, comorbidity, isolation, chronic affective clinic and life dissatisfaction. Self-compassion training (SCT) could be an effective strategy targeting self-criticism, shame and chronic feelings of worthlessness, as well as increasing resilience. In addition, the administration of intranasal oxytocin has proven useful in regulating social cognition, affiliation behaviors and enhancing empathy, key symptoms in this population. This combined intervention could be particularly appropriate for BPD patients.\n\nObjective: The objective of this project is to implement and evaluate the effectiveness of a combined intervention, based on SCT and intranasal oxytocin administration, for the treatment of patients with BPD.\n\nMethodology: Controlled and randomized clinical trial. A self-compassion training of 5 weeks duration plus intranasal oxytocin administration versus SCT plus placebo will be compared in a sample of 80 patients with BPD. Clinical and wellness measures will be evalutated as outcomes.",[177,178],"Self-compassion Training (SCT) Plus Intranasal Oxytocin","Self-compassion Training (SCT) Plus Intranasal Placebo",[180],"oxytocin; self-compassion therapy; controlled clinical trial","2026-04-22",{"date":183,"type":35},"2026-04-27",{"date":185,"type":35},"2024-01-10",{"date":187,"type":23},"2026-08-01",{"name":41,"class":42},{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":12,"sex":18,"minAge":78,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":80,"phases":198,"briefSummary":199,"conditions":200,"keywords":204,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":43},"100635240","pvi-vs-esp-block-for-reducing-bleeding-and-postoperative-pain-in-lumbar-fusion-surgery-100635240","NCT07550114","PVI vs ESP Block for Reducing Bleeding and Postoperative Pain in Lumbar Fusion Surgery.","EFFICACY OF PERIARTICULAR VASOCONSTRICTOR INFILTRATION (PVI) VERSUS ERECTOR SPINAE PLANE BLOCK (ESP) IN REDUCING BLEEDING AND POSTOPERATIVE PAIN CONTROL IN LUMBAR FUSION SURGERY: RANDOMIZED CLINICAL TRIAL.","Inclusion Criteria:\n\n* More than 18 years old.\n* ASA I-III\n* Scheduled primary spinal instrumentation surgery (lumbar\u002Fthoracolumbar fusion)\n* Signed informed consent\n\nExclusion Criteria:\n\n* Allergy\u002Fcontraindication to study drugs (ropivacaine, epinephrine)\n* Coagulopathy.\n* Infection at block site\n* Neuromuscular disease affecting evaluation.\n* Chronic opioid use (\\>30mg morphine equivalents\u002Fday)\n* Cognitive impairment preventing pain reporting.\n* Pregnancy",{"count":197,"type":23},62,[154],"This randomized controlled trial compares periarticular vasoconstrictor infiltration (PVI) versus erector spinae plane block (ESP) to reduce bleeding and postoperative pain in adults undergoing lumbar fusion surgery (up to 3 levels). Patients are randomly assigned 1:1 to receive ultrasound-guided ropivacaine 0.2% + epinephrine 1:200,000: PVI (150-200mL bilateral in retrolaminar, thoracolumbar fascia, supraspinous ligament, subcutaneous planes) or ESP (20mL\u002Fside at transverse processes). Both groups receive standardized general anesthesia (TIVA), multimodal analgesia (dexamethasone, paracetamol, dexketoprofen\u002Fmetamizole, ketamine, magnesium), and tranexamic acid. Multicenter study: Hospital de la Santa Creu i Sant Pau (Barcelona, 32 patients) and Hospital Quirón Salud Murcia (30 patients). Primary outcome: intraoperative blood loss (surgical aspirate minus irrigation + gravimetric gauze weight). Secondary outcomes: Fromme surgical field scale, pain (NRS at REA discharge\u002F24h\u002F48h), opioid consumption (morphine equivalents), PONV\u002Fantiemetic use, drain output, hospital stay, patient satisfaction. N=62 patients (31\u002Farm). Blinded outcome assessment.",[201,202,203],"Surgical Blood Loss","Postoperative Pain","Lumbar Spinal Fusion Surgery",[205,206,207,208,209,210,211,212],"Lumbar fusion","ESP block","PVI block","Intraoperative bleeding","Postoperative pain","WALANT","ropivacaine","epinephrine","2026-04-19",{"date":215,"type":35},"2026-04-24",{"date":217,"type":35},"2026-01-08",{"date":219,"type":23},"2028-03-01",{"name":41,"class":42},{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":18,"minAge":78,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":80,"phases":230,"briefSummary":231,"conditions":232,"keywords":237,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":121},"100632512","validation-of-a-regional-citrate-anticoagulation-protocol-in-critically-ill-patients-on-continuous-renal-replacement-therapy-100632512","NCT07514650","Validation of a Regional Citrate Anticoagulation Protocol in Critically Ill Patients on Continuous Renal Replacement Therapy","CRRT","Inclusion Criteria\n\n* Age ≥18 years\n* Admission to the intensive care unit (ICU)\n* Diagnosis of acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT)\n* Use of regional citrate anticoagulation during CRRT Exclusion Criteria\n* Known allergy or intolerance to citrate\n* Contraindications to citrate anticoagulation (e.g., severe liver failure or severe metabolic disorders affecting citrate metabolism)\n* Pregnancy or breastfeeding",{"count":229,"type":23},43,[154],"The objective of this study is to evaluate the effectiveness of a modified continuous renal replacement therapy (CRRT) protocol in maintaining electrolyte balance in adult patients with acute kidney injury (AKI) admitted to the intensive care unit (ICU).\n\nThe study assesses whether the use of continuous venovenous hemodiafiltration (CVVHDF) with post-filter replacement under citrate anticoagulation reduces electrolyte losses and the need for electrolyte supplementation compared with standard dialytic CRRT.\n\nParticipants receiving standard CRRT will be compared with those treated with the modified protocol.\n\nThe duration of participation corresponds to the period during which CRRT is required. Data collection will cease once CRRT is discontinued.",[233,234,235,236],"Acute Kidney Injury","ICU Patients","Continuous Renal Replacement Therapy (CRRT)","Electrolytes",[238,233,239,240,241,236],"Regional Citrate Anticoagulation","ICU patients","Continuous Renal Replacement Therapy","Diluted citrate","2026-04-01",{"date":244,"type":35},"2026-04-07",{"date":246,"type":35},"2024-11-24",{"date":248,"type":23},"2026-11",{"name":41,"class":42},{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":12,"sex":18,"minAge":258,"maxAge":259,"enrollmentInfo":260,"targetDuration":4,"studyType":80,"phases":262,"briefSummary":264,"conditions":265,"keywords":269,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":279},"100497733","phase-4-fast-track-therapeutic-model-in-acute-complicated-appendicitis-in-pediatrics-100497733","NCT05761080","Fast Track Therapeutic Model in Acute Complicated Appendicitis in Pediatrics","Evaluation of a Therapeutic Strategy to Shorten Hospital Stay in Complicated Pediatric Appendicitis: A Randomized, Parallel, Multicenter, Open-Label Clinical Trial","FTAA","Inclusion criteria:\n\n* Ages 2 to 17 years. Intraoperative diagnosis of complicated appendicitis. Laparoscopic appendectomy. Agreement to participate in the study with signed informed consent.\n\nExclusion criteria:\n\n* Peritonitis with sepsis criteria. Catarrhal or phlegmonous appendicitis. History of cystic fibrosis, Crohn's disease, or transplant that may interfere with the usual postoperative course of laparoscopic appendectomy.\n\nContraindication to the administration of amoxicillin-clavulanic acid. Refusal to participate in the study by parents\u002Flegal guardians.","2 Years","17 Years",{"count":261,"type":23},772,[263],"PHASE4","To evaluate whether a postoperative therapeutic strategy, Fast Track, aimed at shortening hospital stay in pediatric patients undergoing laparoscopic appendectomy for complicated acute appendicitis, yields outcomes that are not inferior to the standard therapeutic model in terms of the combined variable of adverse events within 30 days postoperatively (including postoperative abdominal abscess, peritonitis, surgical wound complications, reintervention, sepsis, or death).",[266,267,268],"Laparoscopic Appendectomy","Complicated Appendicitis","Periappendicular Abscess",[270],"Complicated appendicitis","2026-03-19",{"date":273,"type":35},"2026-03-20",{"date":275,"type":35},"2021-04-22",{"date":277,"type":23},"2027-12",{"name":41,"class":42},7,{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":18,"minAge":78,"maxAge":4,"enrollmentInfo":288,"targetDuration":290,"studyType":25,"phases":4,"briefSummary":291,"conditions":292,"keywords":294,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":305,"locationsCount":121},"100628451","characterization-of-type-1-diabetes-subgroup-an-artificial-intelligence-analysis-of-clinical-and-glucometric-features-100628451","NCT07461805","Characterization of Type 1 Diabetes Subgroup: An Artificial Intelligence Analysis of Clinical and Glucometric Features","Caracterización de Subgrupos de Personas Con Diabetes Tipo 1: análisis de características clínicas y glucométricas Utilizando Una aproximación de Inteligencia Artificial","T1DC","Inclusion Criteria:\n\n* Individuals with type 1 diabetes (T1D) aged 18 years or older.\n* T1D individuals expected to have regular follow-up at the Endocrinology and Nutrition Department of Hospital de la Santa Creu i Sant Pau.\n* Users of continuous glucose monitoring (CGM) systems for at least the last 6 months of 2024.\n* Willingness and ability to provide written informed consent to participate in the study (by the patient or his\u002Fher representative).\n\nExclusion Criteria:\n\n* Presence of severe comorbidities or medical conditions that, in the investigator's judgment, could interfere with participation in the study or the interpretation of results. This circumstance is expected to be exceptional, as the study aims to be as inclusive as possible.",{"count":289,"type":23},800,"4 Years","The goal of this observational study is to characterize different subgroups among patients with type 1 diabetes. The main research question is:\n\nAre there distinct subtypes among people with type 1 diabetes?\n\nParticipants will be invited to take part in the study by allowing access to their health data. They will not be required to undergo any additional examinations, tests, visits, or interventions.",[293],"Type 1 Diabetes Mellitus",[295,296,297,298],"Artificial intelligence","glucometry","Clusters","Type 1 diabetes mellitus","2026-03-06",{"date":301,"type":35},"2026-03-10",{"date":303,"type":35},"2025-11-04",{"date":94,"type":23},{"name":41,"class":42},{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":313,"sex":18,"minAge":78,"maxAge":314,"enrollmentInfo":315,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":317,"conditions":318,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":121},"100627358","oscillometry-and-machine-learning-approaches-100627358","NCT07447596","Oscillometry and Machine Learning Approaches","Feasibility Study of Forced Oscillometry in the Prediction of Chronic Respiratory Diseases Using Machine Learning Approaches","Inclusion Criteria:\n\n* 18 - 90 years\n* Spirometry available\n* Confirmed clinical diagnosis of COPD, asthma, interstitial lung disease according to national or international guidelines\n\nExclusion Criteria:\n\n* Acute respiratory infection",true,"99 Years",{"count":316,"type":23},50,"Unicentric retrospective study designed to analyses the performance of various machine learning approaches to predict patterns of chronic respiratory diseases such as asthma, based mainly on clinical information and respiratory spirometry\u002Foscillometry.",[319],"Asthma COPD","2026-02-26",{"date":322,"type":35},"2026-03-03",{"date":324,"type":35},"2025-10-15",{"date":326,"type":23},"2026-09-01",{"name":41,"class":42},{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":336,"minAge":78,"maxAge":4,"enrollmentInfo":337,"targetDuration":4,"studyType":80,"phases":339,"briefSummary":340,"conditions":341,"keywords":345,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":43},"100600552","phase-2-statin-intervention-for-severe-early-onset-placental-insufficiency-statin-pre-trial-100600552","NCT07098975","Statin Intervention for Severe Early-Onset Placental Insufficiency. (STATIN-PRE Trial)","Statin Intervention for Severe Early-Onset Placental Insufficiency: A Randomized Controlled Trial Assessing Daily Administration as a Treatment Strategy (STATIN-PRE Trial)","STATIN-PRE","Inclusion Criteria:\n\n* Singleton fetus.\n* Between 24+0 to 29+6 weeks of gestation at the inclusion.\n* Early-onset severe PE: women with a diagnosis of severe-preterm PE who are candidates for expectant management and have no clinical indication for immediate delivery, based on the clinical assessments of the attending doctors.\n\nAnd\u002For\n\n* IUGR: Diagnosis of early onset IUGR according to the SMFM classification with umbilical artery Doppler with absent\u002Freversed diastolic flow; or estimated fetal weight \\\u003C10th percentile plus pulsatility index (PI) of umbilical artery Doppler \\>95th percentil.\n* Able to give informed consent.\n\nExclusion Criteria:\n\n* Established maternal or fetal compromise that necessitated immediate delivery\n* Abnormal karyotype, structural abnormalities, or congenital infections.\n* Treatment with pravastatin or other statins prior to inclusion.\n* Lactose intolerance","FEMALE",{"count":338,"type":23},154,[83],"In pregnancies with placental insufficiency, the only available treatment is close monitoring to determine the point at which the risks of preterm birth for the baby are lower than the risks of continuing the pregnancy. Therefore, safely prolonging pregnancy is the current management goal for this condition.\n\nStatins, such as pravastatin, are approved and marketed drugs used to prevent cardiovascular disease. Recent studies suggest that statins may help treat pregnancy complications and prolong pregnancy, thereby avoiding extreme prematurity and improving long-term health outcomes for both mother and baby.\n\nPrevious clinical trials have shown the ability of statins to stabilize angiogenic factors, thus reducing obstetric complications associated with placental insufficiency. In 2015, a study reported that pravastatin was effective in stabilizing blood pressure and reducing proteinuria associated with preeclampsia. More recently, in 2020, it was demonstrated that in pregnant women with fetal growth restriction treated with pravastatin, the sFlt-1\u002FPlGF ratio was lower than in untreated women, indicating a slower progression of placental insufficiency.\n\nThis study proposes administering a daily dose of 40 mg of pravastatin between 24 and 29.6 weeks of gestation to mothers diagnosed with preeclampsia and\u002For fetal growth restriction. One group of women will receive the medication, while another group will receive a visually identical but inactive pill (a placebo), allowing us to determine whether any observed improvement in pregnancy is attributable to the medication. Assignment to the treatment or placebo group will be random, and neither the mothers nor the healthcare professionals caring for them will know which group they are in.\n\nThe investigators also aim to examine whether this intervention during pregnancy protects the cardiovascular system. For this reason, the investigators will assess both the mother and the baby six months after birth using an ultrasound of the heart and blood vessels, and the investigators will also perform a blood test on the mothers. Additionally, the investigators want to explore the needs and expectations of women who experience these complications during pregnancy and postpartum, so that their stories can guide us in finding answers and solutions that are as personalized as possible to the real needs of families. After the visit at six months postpartum, yhe investigators will follow up with annual phone calls over the next four years to check on the participants' health and their baby's. During each call, the investigators will review the participant's health status and talk about how the participant is feeling. All of this will help us ensure that the treatment does not cause any long-term issues and will improve future care for other mothers and babies.\n\nA total of 154 pregnant women are expected to be included in order to meet the study's objectives.",[342,343,344],"Preeclampsia (PE)","Intrauterine Growth Restriction (IUGR)","Placental Insufficiency",[346,347,344,348,349],"Preeclampsia","Intrauterine growth restriction","statins","Pravastatin","2026-02-19",{"date":352,"type":35},"2026-02-23",{"date":354,"type":35},"2026-01-14",{"date":356,"type":23},"2028-07",{"name":41,"class":42},{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":12,"sex":18,"minAge":365,"maxAge":366,"enrollmentInfo":367,"targetDuration":4,"studyType":80,"phases":368,"briefSummary":369,"conditions":370,"keywords":377,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":121},"100621337","comparing-biomarker-guided-dbs-programming-with-standard-clinical-monopolar-programming-100621337","NCT07369310","Comparing Biomarker-Guided DBS Programming With Standard Clinical Monopolar Programming","Randomized Trial on DBS Programming Based on Biomarkers vs. Standard Monopolar Review","Inclusion Criteria:\n\n* Age between 30 and 70 years.\n* Confirmed diagnosis of idiopathic Parkinson's disease according to the MDS diagnostic criteria (Postuma et al., 2015).\n* Indication for deep brain stimulation surgery based on CAPSIT-PD criteria.\n\nExclusion Criteria:\n\n* Presence of severe surgical complications (e.g., intracranial hemorrhage, infection).\n* Postoperative adverse events requiring electrode repositioning.\n* Any other medical or neurological condition that could interfere with safe participation in the trial.","30 Years","70 Years",{"count":105,"type":23},[154],"The goal of this clinical trial is to learn whether an objective, data-guided approach to programming deep brain stimulation (DBS) can improve motor outcomes in people with Parkinson's disease who undergo DBS surgery. The study includes adults aged 30 to 70 years with Parkinson's disease who are candidates for DBS.\n\nThe main questions it aims to answer are:\n\nDoes DBS programming based on objective markers (brain imaging and brain signals) reduce the amount of daily time patients spend in the OFF state more than conventional clinical programming?\n\nDoes this programming approach improve quality of life and motor symptoms compared with standard programming?\n\nResearchers will compare conventional DBS programming based on clinical monopolar review with DBS programming guided by electrode location on neuroimaging and beta brain signals recorded from the implanted device, to see if the objective approach leads to better motor control and less OFF time.\n\nParticipants will:\n\nUndergo DBS surgery using a clinically approved DBS system\n\nBe randomly assigned to one of two DBS programming strategies\n\nWear inertial sensors at home for several days at different time points to objectively measure motor symptoms\n\nAttend scheduled clinical visits for DBS programming and motor and non-motor assessments\n\nHave adaptive DBS activated after 3 months and continue follow-up until 6 months after programming begins",[371,372,373,374,375,376],"Parkinson's Disease","Parkinson","Parkinsons Disease (PD)","Motor Fluctuations","DBS","Deep Brain Stimulation",[371,376,378,379,380,381,382,383,384,385,386,387,388,374,389,390,391,392],"DBS Programming","Monopolar Review","Local Field Potentials","Beta Oscillations","BrainSense","Medtronic Percept","Neuroimaging-Guided Programming","Objective Programming","Adaptive Deep Brain Stimulatoin","Wearable Sensors","Inertial Sensors","OFF Time","Dyskinesia","Neuromodulation","Subthalamic Nucleus","2026-01-26",{"date":395,"type":35},"2026-01-27",{"date":397,"type":23},"2026-03-01",{"date":399,"type":23},"2028-09-01",{"name":41,"class":42},{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":12,"sex":18,"minAge":408,"maxAge":259,"enrollmentInfo":409,"targetDuration":4,"studyType":80,"phases":411,"briefSummary":412,"conditions":413,"keywords":415,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":4},"100620978","effectiveness-of-an-educational-intervention-on-asthmatic-children-in-inhaled-technique-and-adherence-100620978","NCT07364643","Effectiveness of an Educational Intervention on Asthmatic Children in Inhaled Technique and Adherence.","Assessment of Asthma Management in Children Over 6 Years of Age and Their Caregivers. Implications for the Implementation of the SMART Strategy in Pediatrics.","Inclusion Criteria:\n\n* Clinical diagnosis of asthma.\n* Prescribed treatment with inhaled corticosteroid.\n* First-degree relative of the patient.\n\nExclusion Criteria:\n\n. Inability to understand Spanish.","6 Years",{"count":410,"type":23},428,[154],"The goal of this study is to see if a short educational session and demonstration by a nurse can help asthmatic children (6-17 years-old), under hospital control, to manage their asthma better, to use their inhaler correctly, and to know when it should be used.\n\nThe main question it aims to answer is how much improvement is reached on asthma self-management. The comparison group is the same group. Researchers will compare results before and after educational intervention.",[414],"Asthma Childhood",[416,417,418,419],"inhaler technique","treatment adherence","asthma self-management","nursing intervention","2026-01-16",{"date":422,"type":35},"2026-01-23",{"date":424,"type":23},"2026-01",{"date":426,"type":23},"2027-01",{"name":41,"class":42},{"id":429,"slug":430,"hasResults":12,"nctId":431,"briefTitle":432,"officialTitle":432,"acronym":433,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":18,"minAge":78,"maxAge":4,"enrollmentInfo":435,"targetDuration":4,"studyType":80,"phases":437,"briefSummary":438,"conditions":439,"keywords":445,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":451,"leadSponsor":453,"locationsCount":4},"100619381","quantification-of-systemic-congestion-by-ultrasound-as-a-predictor-of-weaning-failure-from-mechanical-ventilation-100619381","NCT07343882","Quantification of Systemic Congestion by Ultrasound As a Predictor of Weaning Failure From Mechanical Ventilation","SCOUT","Inclusion Criteria:\n\n* Patients aged \\> 18 years.\n* Admitted to an Intensive Care Unit (ICU).\n* Requiring invasive mechanical ventilation for more than 48 hours.\n* Meeting the center's standard criteria to begin weaning and undergo an SBT.\n\nExclusion Criteria:\n\n* Inadequate ultrasound window for assessment.\n* Presence of \"do not reintubate\" orders.\n* Patients with a tracheostomy.\n* Presence of atrial fibrillation.\n* Diagnosed liver cirrhosis (portal hypertension).\n* Absence of qualified personnel to perform the ultrasound at the time of the SBT.\n* Denial of informed consent.",{"count":436,"type":23},350,[154],"Mechanical ventilation is an essential, life-saving therapy in the ICU, allowing critically ill patients to rest and recover. Transitioning patients back to spontaneous breathing-known as weaning-is clinically challenging. The first attempt, the Spontaneous Breathing Trial (SBT), fails in 10-30% of cases. Identifying the mechanisms behind failure is crucial, as unsuccessful weaning prolongs ICU stay and increases the risk of reintubation, which worsens prognosis. The SCOUT study aims to improve prediction and management of weaning failure.\n\nThe main objective of the study is to evaluate whether a specific ultrasound-based method, the Venous Excess Ultrasound Score (VExUS), can predict failure of weaning from mechanical ventilation. A key pathophysiological factor is systemic venous congestion. When a patient initiates an SBT, the increased respiratory effort shifts venous return and may precipitate cardiovascular decompensation with pulmonary fluid accumulation, termed weaning-induced pulmonary edema (WIPO). Notably, this may occur even in patients without known cardiac disease.\n\nDetecting clinically relevant congestion before SBT is difficult. Fluid balance and body weight are imprecise, physical examination lacks sensitivity, and biomarkers such as NT-proBNP have limited predictive capacity. VExUS offers a promising, non-invasive approach by directly assessing venous flow patterns in major veins (inferior vena cava, hepatic, portal, and renal veins), providing an estimation of systemic venous pressure and congestion. The central hypothesis is that elevated VExUS grades prior to SBT will identify patients at high risk of failure, enabling proactive optimization and potentially improving outcomes.\n\nSCOUT is designed as a prospective, multicenter, observational study. Standard clinical management of mechanical ventilation and weaning remains unchanged. After informed consent, baseline data will be obtained immediately before SBT, including vital signs, ventilator parameters, blood sampling, and three non-invasive ultrasound assessments: cardiac, pulmonary, and VExUS. During the 30-120-minute SBT, the patient breathes with reduced ventilatory support while their clinical tolerance is evaluated. At the end of the SBT, selected measurements are repeated. Weaning failure is defined as: early termination of SBT due to intolerance, need for invasive or non-invasive ventilation within 48 h after extubation, or death within 48 h. Data are anonymized and stored securely (REDCap) in compliance with Spanish and EU data protection regulations.\n\nThe study is low-risk and provides no direct individual benefit, but may benefit future ICU patients by improving weaning strategies and prognostication.",[440,441,442,443,444],"Weaning Failure","Pulmonary Edema - Acute","Mechanical Ventilation","POCUS","VExUS",[446,447],"Weaning induced pulmonary edema","Venous Excess Ultrasound grading system",{"date":449,"type":35},"2026-01-21",{"date":242,"type":23},{"date":452,"type":23},"2027-06-01",{"name":41,"class":42},{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":458,"acronym":459,"eligibilityCriteria":460,"healthyVolunteers":313,"sex":336,"minAge":78,"maxAge":4,"enrollmentInfo":461,"targetDuration":463,"studyType":25,"phases":4,"briefSummary":464,"conditions":465,"keywords":468,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":477,"locationsCount":121},"100620376","cardiovascular-risk-assessment-in-young-women-after-index-pregnancy-with-and-without-placental-complications-100620376","NCT07356817","Cardiovascular Risk Assessment in Young Women After Index Pregnancy With and Without Placental Complications","CARDIOMOM","Inclusion Criteria:\n\n* Patients who participated in the BiSC (Barcelona Life Study Cohort), EuroPE (Randomized open-label control trial to evaluate if the incorporation of sFlt1\u002FPlGF ratio in the diagnosis and classification of PE improves maternal and perinatal outcomes in women with suspicion of the disease; PI16\u002F00375) and AngioCor (Cardiac dysfunction and remodeling in patients with preeclampsia regulated by antiangiogenic environment: clinical and experimental approach, PI19\u002F00702) cohort studies\n* Who have delivered within the previous 3-6 years.\n* Give written consent when invited to participate in this study protocol.\n\nExclusion Criteria:\n\n* Unwillingness to participate in this study\n* Probability of loss to follow-up.",{"count":462,"type":23},1260,"1 Day","In this project, the investigators aim to study how all these factors determine the cardiovascular status of a total of 1,800 mothers, 3 to 6 years after delivery. In addition, the investigators want to assess whether lifestyle and living conditions after childbirth may improve or worsen this imprint, since women often prioritize their families over themselves, making it more difficult to maintain a healthy lifestyle that could reduce their cardiovascular risk. Furthermore, the investigators will evaluate how environmental exposures influence their health, as well as explore potential strategies for prediction and prevention.\n\nThe goal is to develop an easy-to-use algorithm or test that allows women and their physicians to assess this risk, ideally in the form of a mobile app. Although predictive algorithms for cardiovascular health already exist, most have been developed using predominantly male or older populations, and none have taken into account pregnancy-related events or environmental exposure - both of which are key determinants of women's cardiovascular health.",[466,342,467],"Cardiovascular (CV) Risk","Fetal Weight",[469,470,471],"preeclampsia","Cardiovascular Risk","app","2026-01-12",{"date":449,"type":35},{"date":475,"type":35},"2023-08-28",{"date":68,"type":23},{"name":41,"class":42},{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":18,"minAge":486,"maxAge":4,"enrollmentInfo":487,"targetDuration":4,"studyType":80,"phases":488,"briefSummary":490,"conditions":491,"keywords":502,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":518,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":522,"locationsCount":523},"100610985","phase-3-levetiracetam-to-prevent-seizures-in-symptomatic-alzheimers-disease-in-adults-with-down-syndrome-100610985","NCT07234695","LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome","A Phase III, Randomized, Double-blinded Study of the Efficacy and Safety of LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome (the LESS-AD Trial).","LESS-AD","Inclusion Criteria:\n\n* Diagnosed with Down Syndrome (DS), either with a karyotype or a compatible typical phenotype.\n* Age over 40 years at time of screening.\n* Symptomatic Alzheimer's Disease (AD) dementia, based on change in functionality and neuropsychological tests' results. Different cut-off points will be established to diagnose dementia depending on the level of intellectual disability of the individual, according to previous experience (Benejam et al; 2020): in adults with mild intellectual disability, a CAMCOG-DS score of 80 and an mCRT score of 29 will be chosen, whereas values of 56 and 28, respectively, will be used in subjects with moderate intellectual disability. Doubtful cases (e.g., with compromised functionality, but without alteration in the neuropsychological assessment) or those unable to complete the evaluation will be categorized by consensus among expert clinicians, using all available clinical information.\n* Willing and able caregiver who has daily contact with the study subject.\n* Subjects and caregivers must be able to comply with the prescribed regimen of study treatment throughout the course of the study and meet a minimum required time commitment of biannual in-person visits.\n* Any concurrent treatment for AD approved by the European Medicines Agency (EMA) must be stable for at least 30 days prior to screening and at least 60 days prior to study day 1. Other medications (except for those listed under exclusion criteria) are allowed as long as the dose is stable for 30 days prior to screening.\n* Subjects and\u002For their caregivers must be able to provide their consent before participating in any study-related procedures.\n\nExclusion Criteria:\n\n* Cognitive changes attributable to causes other than AD (for example, but not limited to, uncorrected visual or hearing deficit, severe, untreated sleep apnea or uncontrolled thyroid disorders).\n* Previous history of adult-onset epileptic seizures (over 18 years old).\n* Treatment with any kind of antiepileptic drugs, benzodiazepines, narcotics.\n* Significant comorbidities or analytical abnormalities, such as:\n* Any unstable and\u002For clinically significant medical condition likely to hamper the evaluation of safety and\u002For efficacy of the study (eg, moderate and\u002For severe untreated obstructive sleep apnea, clinically significant reduction in serum B12 or folate levels, clinically significant abnormalities of thyroid function, stroke, or other cerebrovascular conditions), as per investigator's judgement.\n* Severe renal dysfunction (creatinine clearance \\\u003C 30 mL\u002Fmin), which would affect serum levetiracetam levels, or any other medical condition which is determined by the investigators to potentially create an undue risk for an adverse effect.\n* Concomitant or past history psychiatric or neurologic disorder other than those considered to be related to AD (eg, head injury with loss of consciousness, symptomatic stroke, Parkinson's disease, severe carotid occlusive disease, transient ischemic attacks \\[TIAs\\]).\n* Significant risk of suicide, defined using the C-SSRS as the subject answering \"yes\" to suicidal ideation questions 4 or 5 or answering \"yes\" to suicidal behavior within the past 12 months.\n* Deviations from normal values for hematologic parameters, liver function tests, and other biochemical measures, judged to be clinically significant by the investigator.\n* Participation in another clinical trial within 3 months of screening.\n* Hypersensitivity to the active ingredient, other pyrrolidone derivatives, or any of the excipients\n* Pregnant and breastfeeding patients","40 Years",{"count":131,"type":23},[489],"PHASE3","The purpose of this study is to evaluate whether levetiracetam can prevent epileptic seizures in patients with Alzheimer's disease associated with Down syndrome. It will also analyze whether it can delay the neurodegeneration associated with this disease.\n\nPatients will be randomly assigned to one of two groups: one group will receive the active drug (levetiracetam), and the other will receive a placebo.\n\nBoth groups will receive the treatment for 96 weeks. Each patient will participate for a total of 2 years and 5 months.",[492,493,494,495,496,497,498,499,500,501],"Down Syndrome","Down Syndrome (DS)","Down Syndrome (Trisomy 21)","Alzheimer Dementia","Alzheimer Dementia (AD)","Alzheimer Disease","Alzheimer Disease (AD)","Alzheimer Blood Biomarkers","Epilepsy","Seizures",[503,504,505,506,507,508,509,510,511,512,513,514,515,516,517],"Down syndrome","epilepsy","Alzheimer","dementia","levetiracetam","prevention","placebo-controlled","epileptic seizures","Alzheimer's disease markers","phase III","randomized","double-blind","bilateral tonic-clonic seizure","217-pTau","NfL",{"date":472,"type":35},{"date":520,"type":23},"2025-12-22",{"date":356,"type":23},{"name":41,"class":42},5,{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":336,"minAge":78,"maxAge":4,"enrollmentInfo":531,"targetDuration":258,"studyType":25,"phases":4,"briefSummary":533,"conditions":534,"keywords":536,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":121},"100614699","evolution-of-endometriosis-lesions-followed-by-ultrasound-and-quality-of-life-of-patients-factors-that-influence-disease-progression-in-a-prospective-cohort-100614699","NCT07282990","Evolution of Endometriosis Lesions Followed by Ultrasound and Quality of Life of Patients: Factors That Influence Disease Progression in a Prospective Cohort","Evolution of Endometriosis Lesions and Quality of Life of Patients","Inclusion Criteria:\n\n1. Women with a confirmed diagnosis of endometriosis, based on ultrasound criteria. Diagnosis must be confirmed by transvaginal ultrasound with evidence of visible and measurable endometriotic lesions.\n2. Patients over 18 years of age. This criterion ensures that participants can provide informed consent and are of reproductive age, when the effects of endometriosis and its treatments are relevant to the study.\n3. A transvaginal ultrasound performed prior to enrollment showing endometriotic lesions (either endometriomas or deep lesions) with sufficient dimensions and characteristics for evaluation and follow-up.\n4. Patients who do not have an indication for scheduled surgery within the next two years. This ensures that the effects of treatment and the progression of the disease can be evaluated throughout the study follow-up period.\n5. Signed informed consent from the patient, indicating that she has understood the purpose of the study, the procedures involved, and the potential risks.\n\nExclusion Criteria:\n\n1. Patients with an indication for scheduled surgical treatment within the next two years. This includes patients requiring surgery for the removal of endometriotic lesions or to address related complications.\n2. Patients who are unwilling to undergo follow-up transvaginal ultrasound at scheduled visits (6 months, 1 year, 2 years). Ultrasound is essential for assessing disease progression and the impact of treatment.\n3. Patients who are unwilling to participate in the study after receiving all the information and providing their informed consent. Voluntary participation is crucial for the ethics of the study.\n4. Patients with intellectual disabilities or conditions that impair their understanding of the study terms and procedures, which could affect their ability to provide valid informed consent.\n5. Patients who are pregnant or breastfeeding at the time of enrollment. These conditions can influence the course of endometriosis and the response to treatment, and could complicate disease monitoring.\n6. Patients with serious concurrent illnesses or medical conditions that may interfere with the assessment of endometriosis, its progression, or the impact of treatment (e.g., severe chronic inflammatory diseases or cancer).\n7. Patients receiving concurrent treatments not permitted by the study protocol (e.g., experimental treatments for endometriosis or related conditions) that may interfere with the interpretation of the results.",{"count":532,"type":23},100,"The goal of this prospective cohort study is to determine the factors that influence the progression of endometriosis and the quality of life of patients.\n\nThe main questions it aims to answer are:\n\n1. Is endometriosis a progressive disease?\n2. Is the progression of lesions visualized by ultrasound dependent on the medical treatment received?\n3. Does the clinical progression of patients correlate with the progression of lesions visualized on transvaginal ultrasound?\n4. Is ultrasound follow-up necessary for patients?\n5. Could clinical follow-up alone be safe for selected patients?\n\nResearchers will follow up a prospective cohort of 100 patients diagnosed with deep infiltrating endometriosis (DIE) +\u002F- endometriomas during 2 years, collecting data regarding their ultrasound exam and their symptoms and quality of life at stablished controls at recruitment, 6 months, 12 months and 24 months.",[535],"Endometriosis",[535,537,538,539,540],"Ultrasound","QoL","Progression","Ovarian reserve","2025-12-14",{"date":543,"type":35},"2025-12-19",{"date":545,"type":23},"2025-12",{"date":547,"type":23},"2028-05",{"name":41,"class":42},{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":555,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":18,"minAge":78,"maxAge":4,"enrollmentInfo":557,"targetDuration":4,"studyType":80,"phases":559,"briefSummary":560,"conditions":561,"keywords":563,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":121},"100614007","phase-4-evaluation-of-two-different-regimens-of-the-antiarrhythmic-drug-amiodarone-to-maintain-normal-sinus-rhythm-after-electrical-cardioversion-in-patients-with-persistent-atrial-fibrillation-100614007","NCT07273994","Evaluation of Two Different Regimens of the Antiarrhythmic Drug Amiodarone to Maintain Normal Sinus Rhythm After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation","Multicenter Randomized Clinical Trial To Evaluate Two Different Amiodarone Regimens To Maintain Sinus Rhythm After Electrical Cardioversion In Persistent Atrial Fibrillation","PERIVERSION-2","Inclusion Criteria\n\n1. Patients aged ≥ 18 years\n2. Documented persistent atrial fibrillation (≥ 7 days in duration)\n3. Electively referred for Electrical Cardioversion\n4. Signed informed consent.\n\nExclusion Criteria\n\n1. Urgent electrical cardioversion\n2. Atrial fibrillation post-cardiac surgery\n3. Previous myocardial infarction\n4. New York Heart Association (NYHA) Class IV heart failure\n5. Left ventricular ejection fraction (LVEF) \\\u003C45%\n6. Significant left ventricular hypertrophy (wall thickness ≥ 15mm)\n7. Hyperthyroidism or hypothyroidism\n8. Known hepatobiliary disease (acute hepatitis, cirrhosis...) or ALT\u002FAST \\> 3 x upper limit of normal (ULN)\n9. Allergy, intolerance, or known hypersensitivity to study medications\n10. Women of childbearing potential unwilling to use contraceptive measures and breastfeeding women.\n11. Participation in another clinical trial involving investigational drugs\n12. Life expectancy less than 12 months\n13. Rheumatic mitral stenosis of any degree or severe mitral or aortic valve dysfunction.\n14. Patients with contraindications to amiodarone, such as uncontrolled thyroid dysfunction, severe sinus bradycardia, second- or third-degree AV block without a pacemaker, and a history of amiodarone-induced pulmonary toxicity.\n15. Patients in whom chronic amiodarone treatment previously failed to maintain sinus rhythm\n16. Patients with abnormal baseline QTc (\\>450 ms in males and \\>470 in females) or abnormal ECG that precludes QTc assessment\n17. Patients requiring concomitant medications that have a higher risk of QTc prolongation.\n18. Patient do not have a smart mobile phone or do not know how to use it adequately.",{"count":558,"type":23},312,[263],"\\---\n\nThe goal of this clinical trial is to learn if reduced doses of amiodarone can treat atrial fibrillation (AF) effectively while minimizing toxic side effects in patients with persistent AF after electrical cardioversion. The main questions it aims to answer are:\n\n* Can a reduced dose of amiodarone (100 mg\u002Fday) maintain sinus rhythm as effectively as the standard dose (200 mg\u002Fday) 12 months post electrical cardioversion?\n* What are the adverse effects of the standard and reduced doses of amiodarone during 12 months post electrical cardioversion?\n* How do genetic polymorphisms affect the efficacy and safety of amiodarone?\n* How do amiodarone plasma levels correlate with the maintenance of sinus rhythm and genetic polymorphisms?\n\nResearchers will compare the standard dose (200 mg\u002Fday) to the reduced dose (100 mg\u002Fday) to see if the reduced dose offers a better balance between efficacy and safety.\n\nParticipants will:\n\n* Be treated with full dose amiodarone (200 mg\u002Fday) during the first month after electrical cardioversion.\n* Be randomized to either continue with the full dose (200 mg\u002Fday) or switch to the reduced dose (100 mg\u002Fday).\n\nThe study is a multicenter, randomized clinical trial involving 312 patients with persistent AF after successful electrical cardioversion. Participants will be followed for 12-18 months to monitor the recurrence of AF and adverse effects.",[562],"Persistent Atrial Fibrillation",[564,565,566,567,568],"Atrial fibrillation","Electrical cardioversion","Amiodarone","Pharmacogenetics","Adverse effects","2025-12-09",{"date":571,"type":35},"2025-12-10",{"date":573,"type":35},"2025-11-01",{"date":575,"type":23},"2028-04",{"name":41,"class":42},{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":583,"eligibilityCriteria":584,"healthyVolunteers":12,"sex":336,"minAge":78,"maxAge":4,"enrollmentInfo":585,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":587,"conditions":588,"keywords":590,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":43},"100615531","comprehensive-assessment-of-first-trimester-pregnancy-loss-100615531","NCT07293819","Comprehensive Assessment of First Trimester Pregnancy Loss","Comprehensive Assessment of First Trimester Pregnancy Loss: Analyzing Its Impact and Biological Pathways to Develop Tailored Management Care Strategies (The FIRST-CARE Study)","FIRST-CARE","Female participants:\n\nInclusion Criteria:\n\n* Women aged 18 years or older.\n* Diagnosis of missed miscarriage in the first trimester (\\\u003C14 weeks of gestation) confirmed by ultrasound.\n* Presence of an intrauterine pregnancy with fetal demise (clinical pregnancy loss).\n* Willing and able to provide written informed consent.\n* Ability to understand and complete study procedures.\n\nExclusion Criteria:\n\n* Multiple pregnancy (twins or more).\n* Ectopic pregnancy.\n* Molar pregnancy (complete or partial hydatidiform mole).\n* Ongoing pregnancy with fetal cardiac activity.\n* Inability or unwillingness to comply with study procedures or follow-up.\n\nMale participants: no specific inclusion or exclusion criteria will apply to male partners, since the main inclusion criteria is a clinical pregnancy loss.",{"count":586,"type":23},225,"The FIRST-CARE Study is a prospective research project conducted at Hospital de la Santa Creu i Sant Pau (Barcelona, Spain), aimed at better understanding the causes and consequences of first-trimester pregnancy loss (miscarriage).\n\nMiscarriage is a common event that affects about 15% of clinically recognized pregnancies and can have both physical and emotional consequences for women and their partners. However, many questions about its causes remain unanswered, and most women do not receive a clear explanation or personalized support after experiencing a loss.\n\nThis study will include 225 women who have experienced a miscarriage during the first 14 weeks of pregnancy. Two groups will be studied: those who have had a miscarriage for the first time and those with a history of recurrent pregnancy loss (defined as two or more previous miscarriages). The aim is to investigate a wide range of possible causes - including genetic, hormonal, immune, cardiovascular, placental, and psychological factors - in order to improve diagnosis and develop more personalized care strategies.\n\nParticipants will undergo a comprehensive evaluation including ultrasound, blood tests, genetic testing, and psychological assessments. In some cases, their partners will also be invited to participate. Women will be followed for one year to assess their mental well-being and reproductive outcomes, such as the chance of getting pregnant again and the outcome of future pregnancies.\n\nThe study will also create a biobank of biological samples to support future research in the field of pregnancy loss.\n\nBy combining clinical evaluations, laboratory tests, and personal experiences, this study aims to uncover new insights into why miscarriages happen and how to better support women and couples going through this experience. The ultimate goal is to provide better diagnostic tools, care pathways, and support systems to reduce the emotional burden of miscarriage and improve reproductive health outcomes.",[589],"Miscarriage in First Trimester",[591,592,593,594,595,596,597,598,599,600],"Miscarriage","First-trimester","Genetic testing","angiogenic markers","pregnancy loss","perinatal grief","reproductive immunology","anti-phospholipid syndrom","cell-free DNA","chorionic villous sampling","2025-12-07",{"date":543,"type":35},{"date":604,"type":35},"2025-10-02",{"date":606,"type":23},"2029-06",{"name":41,"class":42},{"id":609,"slug":610,"hasResults":12,"nctId":611,"briefTitle":612,"officialTitle":613,"acronym":614,"eligibilityCriteria":615,"healthyVolunteers":12,"sex":18,"minAge":616,"maxAge":4,"enrollmentInfo":617,"targetDuration":4,"studyType":80,"phases":619,"briefSummary":620,"conditions":621,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":624,"startDateStruct":626,"completionDateStruct":627,"leadSponsor":628,"locationsCount":4},"100613704","swaddy-a-neonatal-positioning-device-100613704","NCT07270055","Swaddy, a Neonatal Positioning Device.","Effect of Neonatal Device Swaddy® on the Stress Level of Preterm Newborns: A Randomized Clinical Trial.","Swaddy","Inclusion Criteria:\n\n* Newborns weighing ≤1500 grams at birth admitted to the NICU. • Patients who are in an incubator.\n\nExclusion Criteria:\n\n* Hemodynamic instability.\n\n  * Be a carrier of CPAP or nasal BIPAP with a cap (because the CPAP\u002FBIPAP already has a built-in cap, just like Swaddy).\n  * Be in treatment with phototherapy.","3 Days",{"count":618,"type":23},56,[154],"The objective of this clinical trial is to evaluate the effect of positional restraint on the stress level of preterm newborns, resting in the incubator. The main question sought to be answered is: The stress level of the preterm newborn will decrease with swaddy® containment, compared to standard care, and both with similar safety.\n\nParticipants will remain in the incubator for 3 consecutive hours and the level of stress in the same patient will be evaluated, one day with containment and another day without containment.",[622],"Stress","2025-12-04",{"date":625,"type":35},"2025-12-08",{"date":545,"type":23},{"date":277,"type":23},{"name":41,"class":42},{"id":630,"slug":631,"hasResults":12,"nctId":632,"briefTitle":633,"officialTitle":634,"acronym":4,"eligibilityCriteria":635,"healthyVolunteers":12,"sex":18,"minAge":78,"maxAge":314,"enrollmentInfo":636,"targetDuration":4,"studyType":80,"phases":638,"briefSummary":639,"conditions":640,"keywords":645,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":651,"lastUpdatePostDateStruct":652,"startDateStruct":653,"completionDateStruct":655,"leadSponsor":657,"locationsCount":121},"100600126","adhesive-devices-versus-elastic-devices-for-urinary-catheter-securement-in-critically-ill-patients-experimental-study-100600126","NCT07093437","Adhesive Devices Versus Elastic Devices for Urinary Catheter Securement in Critically Ill Patients Experimental Study","Dispositivos Adhesivos Frente a Dispositivos elásticos Para la sujeción de la Sonda Urinaria en el Paciente crítico Estudio Experimental","Inclusion Criteria:\n\n* Age \\> 18 years\n* Pacients with an urinary catheter inserted within the past 24 hours\n* Expected duration of catheterization \\>48 hours\n* Estimated ICU lenght os stay \\> 48 hours\n\nExclusion Criteria:\n\n* Known allergy to adhesive tape\n* Patients with lesions at the urinary meatus, ongoing urinary tract infection or suspected infection\n* Presence of urological or prostatic pathology\n* Any condition that prevents securing the urinary catheter to the thigh, such as wounds, burns, or amputations",{"count":637,"type":23},188,[154],"Nowadays there are two types of urinary catheter securement devices, adhesive and elastic bands. The goal of this clinical trial is to determine which type of device-adhesive or elastic-is more effective for securing urinary catheters in critically ill patients. The study also aims to evaluate the prevention of urethral meatus injuries, patient discomfort, and the incidence of catheter-associated urinary tract infections .\n\nThe main questions the trial aims to answer are:\n\n* Which device type better prevents injuries to the urethral meatus?\n* Which device reduces discomfort for patients?\n* Which device lowers the incidence of catheter-associated urinary tract infections?\n\nParticipants will:\n\n* Use either an adhesive or an elastic device to secure their urinary catheter during their stay in critical care\n* Be monitored regularly to assess any injuries, discomfort, or infections related to the catheter\n* Provide feedback on their comfort and any complications experienced, if they are able to communicate",[641,642,643,644],"Pressure Injuries","Pain","Catheter-Associated Urinary Tract Infection","Medical Device Site Injury",[646,647,648,649,650],"Urinary catheter securement","Urinary catheter fixation","Catheter-associated urinary tract infections","pain","Meatal pressure injuries","2025-12-03",{"date":571,"type":35},{"date":654,"type":35},"2025-09-22",{"date":656,"type":23},"2026-10-30",{"name":41,"class":42},{"id":659,"slug":660,"hasResults":12,"nctId":661,"briefTitle":662,"officialTitle":663,"acronym":664,"eligibilityCriteria":665,"healthyVolunteers":12,"sex":18,"minAge":78,"maxAge":4,"enrollmentInfo":666,"targetDuration":463,"studyType":25,"phases":4,"briefSummary":668,"conditions":669,"keywords":675,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":681,"lastUpdatePostDateStruct":682,"startDateStruct":684,"completionDateStruct":686,"leadSponsor":688,"locationsCount":121},"100614795","suicidal-ideation-framework-grounded-theory-study-catalonia-100614795","NCT07284238","Suicidal Ideation Framework: Grounded Theory Study, Catalonia","Process of Configuring the Suicidal Ideation Framework: A Grounded Theory Study in Catalonia, Spain","SUIF-GT-CAT","Inclusion Criteria:\n\n* Adults ≥18 years of age.\n* Usual residence in Catalonia (Spain).\n* Ability to understand, speak, read, and write in Catalan or Spanish.\n* Belonging to one of the three defined analytical groups:\n\n(A) Individuals who have attempted suicide within the past 6 months to 3 years. (B) Members of their family, social, or community support networks. (C) Healthcare professionals directly involved in the care of individuals who have attempted suicide.\n\n* Demonstrated clinical\u002Femotional stability ensuring safe participation, as confirmed by the referring clinician.\n* For individuals with lived experience (Group A): at least 6 months since the last suicide attempt or acute clinical crisis.\n* For support networks (Group B): having maintained meaningful proximity or involvement during or after the suicide attempt.\n* For healthcare professionals (Group C): minimum of 1 year of professional experience in mental health care.\n\nExclusion Criteria:\n\n* Presence of acute clinical decompensation preventing safe participation.\n* Active suicidal risk or acute crisis at the time of recruitment.\n* Acute vulnerability identified during screening.\n* Inability to provide informed consent.\n* Direct hierarchical dependence or conflict of interest with the research team (for Group C).",{"count":667,"type":23},45,"This doctoral project aims to develop a comprehensive theoretical model of the process through which the suicidal ideation framework is configured as a symbolic, narrative, and relational expression, adopting a multiperspective approach that spans the suicide attempt and the stages of care and recovery. Moving away from biomedical reductionisms, this investigation seeks to identify shared meaning-making nuclei and discursive fractures that reflect the inherent conflictuality of the suicidal act.\n\nGrounded in the integration of the theoretical frameworks previously outlined, this study adopts an interpretive-constructivist approach. Phase 1 will include studies conducted in OECD countries, providing a broad and conceptually diverse interpretive foundation. Phase 2, conducted in Catalonia, will deepen situated configurations, assuming that local sociocultural frameworks act as interpretive prisms for globally relevant phenomena.\n\nOverall, this theoretical-methodological architecture not only ensures conceptual robustness and coherence, but also articulates an ethical and epistemic commitment to understanding suicide through the complexity of its human textures. By centering suffering, listening to historically silenced voices, honoring the singularity of each life trajectory, and grounding the inquiry in an ethics of care, this study aims to transcend a merely technical-instrumental logic of knowledge.",[670,671,672,673,674],"Suicide","Suicide Attempt","Suicide Ideation","Suicide Risk","Suicide Prevention",[676,670,677,678,679,680],"Suicidal Ideation","Meta-synthesis","Grounded Theory","Mental Health Nursing","High-Income Countries","2025-12-02",{"date":683,"type":35},"2025-12-16",{"date":685,"type":23},"2026-03",{"date":687,"type":23},"2027-09",{"name":41,"class":42},{"id":690,"slug":691,"hasResults":12,"nctId":692,"briefTitle":693,"officialTitle":694,"acronym":4,"eligibilityCriteria":695,"healthyVolunteers":12,"sex":18,"minAge":78,"maxAge":4,"enrollmentInfo":696,"targetDuration":4,"studyType":80,"phases":698,"briefSummary":699,"conditions":700,"keywords":702,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":707,"lastUpdatePostDateStruct":708,"startDateStruct":710,"completionDateStruct":712,"leadSponsor":714,"locationsCount":121},"100610986","feeling-safe-study-100610986","NCT07234708","Feeling Safe Study","Feeling Safe: Feasibility and Acceptability Study Evaluating a New Psychological Intervention for People With Psychosis and Positive Delusional Symptoms","Inclusion Criteria:\n\n* Men and women aged 18 years and older\n* Diagnosis of schizophrenia spectrum disorders and other psychotic disorders according to DSM-5\n* Score ≥ 4 on the delusions item of the Positive and Negative Syndrome Scale (PANSS)\n* Presence of ideas of persecution with a degree of conviction \\> 60% in the last 3 months\n\nExclusion Criteria:\n\n* Presence of intellectual disability\n* Meet DSM-5 criteria for other mental health disorders, except for substance-related and addictive disorders",{"count":697,"type":23},35,[154],"The goal of this study is to assess the acceptability and satisfaction with the psychological intervention Sentirnos Seguros (Feeling Safe) in people with psychotic disorders and positive delusional symptoms.\n\nThe main questions it aims to answer are:\n\n* Study participants will report high levels of acceptability and satisfaction with the Sentirnos Seguros programme.\n* The Sentirnos Seguros intervention will be beneficial for participants at a clinical and functional level, with higher scores in the post-treatment phase compared to the pre-treatment phase.",[701],"Schizophrenia and Schizophrenia Spectrum Psychosis",[703,704,705,706],"Feeling Safe","Schizophrenia","Acceptability","Feasibility","2025-11-18",{"date":709,"type":35},"2025-11-21",{"date":711,"type":35},"2025-07-01",{"date":713,"type":23},"2028-05-01",{"name":41,"class":42},""]